Ziyan Zheng
Ziyan Zheng has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Qingsong Yu
The State Key Laboratory of Organic-Inorganic Composites, Beijing Laboratory of Biomedical Materials, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China
3 shared publications Zhihua Gan
The State Key Laboratory of Organic−inorganic Composites, Beijing Laboratory of Biomedical Materials, College of Life Science and Technology
3 shared publicationsJiawei Chen
The State Key Laboratory of Organic−inorganic Composites, Beijing Laboratory of Biomedical Materials, College of Life Science and Technology
2 shared publicationsYan Kang
The State Key Laboratory of Organic−inorganic Composites, Beijing Laboratory of Biomedical Materials, College of Life Science and Technology
2 shared publicationsBangju Wang
College of Informatics
1 shared publicationChanyuan Jin
Peking University School and Hospital of Stomatology
1 shared publication
Latest Publications
- 18 May 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (21) , 29772-29793
Nano STING Agonist Inhibits Brain Metastases of Solid Tumors through Synergistic Chemotherapy, STING Activation, and Vascular Disruption
Brain metastases (BrM) represent a frequent and devastating complication of advanced solid tumors, characterized by poor prognosis and limited therapeutic options due to the restrictive blood-brain barrier and an immunosuppressive tumor microenvironment (TME). Although the stimulator of interferon genes (STING) pathway is a promising immunotherapeutic target, its clinical application has been hampered by systemic toxicity, inadequate tumor selectivity, and insufficient delivery to intracranial sites. To overcome these challenges, we developed a composite nanosystem, (PC-A)/M nanoparticles, for the targeted codelivery of the STING agonist diABZI and paclitaxel (PTX). This system employs a dual-responsive mechanism based on pH and glutathione (GSH), where the nanoparticle structure first dissociates in the acidic TME to facilitate cellular uptake and subsequently releases its therapeutic cargo in response to the elevated intracellular GSH levels of cancer cells. PTX induces immunogenic cell death and direct apoptosis, while the STING agonist disrupts neovasculature and activates innate immunity to reprogram the local immune environment. This synergistic combination promotes dendritic cell maturation, M1 macrophage polarization, and cytotoxic T-cell recruitment. Our strategy aims to concurrently target primary tumors and BrM, establishing a durable antitumor immune response, and establishes a promising therapeutic strategy for solid tumor BrM.
- 18 May 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (21) , 29772-29793
Nano STING Agonist Inhibits Brain Metastases of Solid Tumors through Synergistic Chemotherapy, STING Activation, and Vascular Disruption
Brain metastases (BrM) represent a frequent and devastating complication of advanced solid tumors, characterized by poor prognosis and limited therapeutic options due to the restrictive blood-brain barrier and an immunosuppressive tumor microenvironment (TME). Although the stimulator of interferon genes (STING) pathway is a promising immunotherapeutic target, its clinical application has been hampered by systemic toxicity, inadequate tumor selectivity, and insufficient delivery to intracranial sites. To overcome these challenges, we developed a composite nanosystem, (PC-A)/M nanoparticles, for the targeted codelivery of the STING agonist diABZI and paclitaxel (PTX). This system employs a dual-responsive mechanism based on pH and glutathione (GSH), where the nanoparticle structure first dissociates in the acidic TME to facilitate cellular uptake and subsequently releases its therapeutic cargo in response to the elevated intracellular GSH levels of cancer cells. PTX induces immunogenic cell death and direct apoptosis, while the STING agonist disrupts neovasculature and activates innate immunity to reprogram the local immune environment. This synergistic combination promotes dendritic cell maturation, M1 macrophage polarization, and cytotoxic T-cell recruitment. Our strategy aims to concurrently target primary tumors and BrM, establishing a durable antitumor immune response, and establishes a promising therapeutic strategy for solid tumor BrM.
- 23 September 2025
- Published by Elsevier in Biomaterials
- Vol. 327, 123730
Dual-responsive nanoparticle system for enhanced blood-brain barrier crossing and glioblastoma penetration
- 23 September 2025
- Published by Elsevier in Biomaterials
- Vol. 327, 123730
Dual-responsive nanoparticle system for enhanced blood-brain barrier crossing and glioblastoma penetration
- 15 March 2024
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 7 (24) , 28027-28043
Functionalized Non-Glass Fiber Nanoporous Separator for High-Performance Aqueous Zinc Ion Batteries
- 15 March 2024
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 7 (24) , 28027-28043
Functionalized Non-Glass Fiber Nanoporous Separator for High-Performance Aqueous Zinc Ion Batteries
- 1 January 2022
- Published by Elsevier in Biomaterials
- Vol. 280, 121305
Cascade-responsive nano-assembly for efficient photothermal-chemo synergistic inhibition of tumor metastasis by targeting cancer stem cells
- 1 January 2022
- Published by Elsevier in Biomaterials
- Vol. 280, 121305
Cascade-responsive nano-assembly for efficient photothermal-chemo synergistic inhibition of tumor metastasis by targeting cancer stem cells